Success Stories: A Chinese Assistant Director in Medicinal Chemistry with 3 Funding Grants, Gets NIW Approval and Retains Us for EB1-A for Our Diligent Team of Experts
Client’s Testimonial:
“Thank you for all the help with my case preparation. It has been a very pleasant experience.”
On August 25th, 2021, we received another EB-2 NIW (National Interest Waiver) approval for an Assistant Director in the Field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Position at the Time of Case Filing: Assistant Director
Country of Origin: China
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: August 25th, 2021
Processing Time: 10 months, 20 days
Case Summary:
“Given the high incidence of tuberculosis and the growing frequency of drug resistance worldwide, it is imperative to support researchers who are advancing research related to the development of novel and effective drugs for treating such infectious diseases. [The client’s] outstanding study of two novel drug targets for tuberculosis is precisely the research that we need in the scientific community. As such the continuation of [client’s] research benefits the lives of countless people across the globe.”
“Drug resistance against the currently-used therapy has elevated the need for developing novel antimicrobial therapies which work via different pathways. [Client’s] medicinal chemistry research is of extreme value in this respect as he has established novel drugs to be tested for the treatment of malaria. He has developed novel chemical entities, which have demonstrated the ability to eliminate malaria parasites via a novel mode of action, thereby benefiting the patients who are resistant to current therapies. Therefore, [client’s] research is fundamental to the well-being of Americans, and he must be allowed to continue his studies that are providing functional solutions to increasing drug resistance against fatal diseases such as malaria.”
These are two quotations taken from the letters of support that our client, an assistant director in medicinal chemistry obtained at our suggestion. Both of which are ample proof to ascertain the global and local value of his research in the proposed field. He intends to continue to pursue research related to the development of drug candidates to treat infectious diseases, CNS disorders, and cancers, in particular, designing and synthesizing drug candidates for treating lung cancer, Parkinson’s disease, multiple myeloma, and COVID-19. His research advancing his proposed endeavor is of great importance because of its value to global treatment efforts of deadly diseases, including malaria and tuberculosis.
All of this information was gathered along with his publication count and citation records, as well as his review and funding experience to show that his expertise was of value to both academics and the government. We gathered that his research has resulted in 7 peer-reviewed journal articles (3 of them first-authored) and 1 book chapter and these publications have been cited a total of 134 times according to Google Scholar. He has also been regularly invited to conduct peer review for elite journals in the field making him complete 8 peer reviews to date.
On the other hand, due to its clear national importance, his research has in fact been supported with 3 separate funding from the National Institutes of Health (NIH) and the Army Medical Research and Materiel (Development) Command (USAMRDC). These organizations are all devoted to improving quality of life, treating illness and disease, and driving scientific discovery in the U.S.
Thus, our experts were able to help him prove beyond reasonable doubt that his work was of importance to the U.S. and should thus be allowed to continue on U.S. soil. We are grateful to him for retaining us for his EB1-A approval as well which we won for him recently in April 2022.